Notable Mergers and Acquisitions of the Day 9/10: IMCL/BMY, VSH/IRF, MSFT/SRVY
More News related to BMY
- New Television Campaign in Mandarin to Educate Chinese Americans about Chronic Hepatitis B
- Exelixis and Bristol-Myers Squibb to Co-Develop XL413, a Selective Cdc7 Inhibitor
- Bristol-Myers Squibb to Present at Healthcare Conference
- Tekmira Pharmaceuticals Corporation Announces Third Quarter 2008 Operating Results and Provides Program Update
- Athersys Announces Clinical Development Milestone in Bristol-Myers Squibb Discovery Alliance
More News related to IMCL
- NASDAQ OMX and Leerink Swann to Co-Host Healthcare Industry Forum
- Lilly Completes Cash Tender Offer for ImClone Systems
- ImClone Systems' State-of-the-Art Manufacturing Facility Receives FDA Approval for Multi-Product Biologics Production
- Randomized Phase 2 Study of IMC-A12 for HER2-Expressing Advanced Breast Cancer Commences Patient Enrollment
- ImClone Systems Announces Clearance of Tender Offer by German Federal Cartel Office
More News related to IRF
- International Rectifier to Present at Upcoming Investment Conferences
- Matrix Upgrades and Downgrades for November 25, 2008
- IR's Control ICs for Energy-Efficient Fluorescent Ballasts Slash Component Count; Increase Reliability and Performance
- International Rectifier (IRF) Reports In-Line Q1 Loss of $0.06
- International Rectifier Announces First Fiscal Quarter Results
More News related to Special Reports
- After-Hours Movers 12/05: Actuate (ACTU) Up On Higher Tender Offer, RF Micro (RFMD) Lower on Guidance
- Trading Radar for 12/05: Big Lots (BIG), Flow Int'l (FLOW), Blyth (BTH) Report; Nonfarm Payrolls, Unemployment Rate, Consumer Credit Due
- Unusual 11 Mid-Day Movers 12/04: DXCM, TLB, PRKR, PSS Higher; CRUS, DMND, ITWO, DDMX Lower
- Notable Analyst Rating Changes 12/04: AMZN, YRCW, GPN, TRI Upgraded; DMND, DOX, FMCN, ISIL Downgraded
- Morning Movers 12/04: Merck (MRK) Lower On Guidance, Amazon.com (AMZN) Higher On Upgrade
- ImClone Systems (NASDAQ: IMCL) Chairman, Carl Icahn, stated that the Special Committee of ImClone's Board of Directors has informed Bristol-Myers Squibb Company (NYSE: BMY) that it has determined that the $60 per share unsolicited offer is inadequate.
Mr. Icahn also announced he has had several conversations with the Chief Executive Officer of a large pharmaceutical company. As a result of such conversations, the pharmaceutical company has submitted a proposal, subject to due diligence, but not subject to financing, to acquire ImClone for $70 per share in cash. The Special Committee has determined, subject to the execution of a confidentiality agreement, to allow this company to conduct due diligence for a two week period, subject to extension by mutual consent. No determination has been made as to whether $70 per share would be adequate.
- Vishay Intertechnology, Inc. (NYSE: VSH) increased the price of its all-cash proposal to acquire all of the outstanding shares of International Rectifier Corporation (NYSE: IRF) common stock to $23.00 per share.
This is up from the $21.22 per share past offer which International Rectifier rejected.
Shares of International Rectifier closed at $21.10 yesterday.
- Microsoft Corp. (Nasdaq: MSFT) and Greenfield Online Inc. (Nasdaq: SRVY) today announced that in connection with the acquisition agreement between the two companies, announced on Aug. 29, 2008, Microsoft has signed an agreement to sell the Greenfield Online Internet survey solutions business to ZM Surveys LLC, a private equity investment partnership focused on entertainment and media investments.
The agreement with ZM Capital is subject to customary closing conditions, including a financing contingency. Microsoft's acquisition of Greenfield Online is not contingent on the closing of the sale of ISS to ZM Capital. The merger of Greenfield Online and Microsoft and Microsoft's sale of the ISS business are expected to close simultaneously in Q408.
Related Categories
Special ReportsStocks Mentioned
-1.00
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
